Resolution had previously raised £22m in Series A funding in 2020. Image credit: Watchara Ritjan / Shutterstock.

Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies.

The UK-based company plans to use the money to finance the Phase I/II EMERALD trial for its lead candidate, RTX001, as a treatment for end-stage liver disease. Resolution also intends to direct the funds to expand its pipeline in other inflammatory and fibrotic indications, including graft-vs-host disease (GvHD) and lung fibrosis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

RTX001 is an engineered autologous macrophage cell therapy. Macrophages act as effector cells of the innate immune system and play an important role in mediating inflammation and eliminating foreign organisms.

RTX001 is designed to decrease fibrosis and inflammation in patients with end-stage liver disease. The open-label Phase I/II EMERALD trial will evaluate the therapy in the indication, with recruitment expected to start across the UK and Spain by the end of the year. The trial’s primary endpoint will measure clinical events including all-cause mortality.

Resolution previously raised £22m in Series A funding in 2020. Both financing rounds were led by Syncona, a UK-based investment fund. Sycona has a portfolio of pharmaceutical startups, including iOncura, which raised $86m in Series B in June.

Another company developing macrophage therapies is Carisma Therapeutics. The company’s portfolio consists of chimeric antigen receptor macrophage and monocyte (CAR-M) therapies. In September, Carisma signed a discovery and licensing agreement with Moderna for two CAR-M therapies for treating autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The cell and gene therapy market is forecasted to be worth over $81bn by 2029, as per GlobalData’s sales and forecast database. Multiple companies have invested in bolstering their cell and gene therapy pipeline.

GlobalData is the parent company of Pharmaceutical Technology.

In December 2023, AstraZeneca signed a $1.2bn deal to acquire China-based Gracell Biotechnologies. Gracell’s lead asset is a dual B cell maturation antigen (BCMA) and CD19-targeting CAR-T cell therapy, GC01F. The therapy is being investigated in multiple indications including multiple myeloma and systemic lupus erythematosus (SLE).

Earlier this year, Genentech signed a $644m collaboration agreement with biotech GenEdit to use the latter’s non-viral delivery platform for gene editing therapies against autoimmune diseases.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.